Proteasome inhibitors are one of the most important classes of agents to have emerged for
the treatment of multiple myeloma in the past two decades, and now form one of the …

Substantial improvements in survival have been seen in multiple myeloma (MM) over recent
years, associated with the introduction and widespread use of multiple novel agents and …

We sought a regimen that incorporates optimal novel agents and balances efficacy with
toxicity in transplant‐ineligible multiple myeloma (MM) patients. Our study evaluated …

Multiple myeloma is the second most frequent hematological disease. The introduction of
melphalan as high-dose therapy followed by autologous hematopoietic cell transplantation …

Proteasome inhibitors (PIs) are a backbone of multiple myeloma (MM) therapy. The
proteasome harbors six proteolytically active subunits (β1, β2, β5), while β5 was identified …

Multiple myeloma is a disease typical of the elderly, and, because of the increase in life
expectancy of the general population, its incidence is expected to grow in the future. Elderly …

During the last few years, several new drugs have been introduced for treatment of patients
with multiple myeloma, which have significantly improved treatment outcome. All of these …

Introduction: There is now 16 years' worth of established results of various trials
demonstrating the bortezomib efficiency in the treatment of multiple myeloma. Over this time …

Cardiovascular disease in patients with multiple myeloma may derive from factors unrelated
to the disease (age, diabetes, dyslipidemia, obesity, prior cardiovascular diseases), related …

Marizomib (MRZ) is an irreversible, pan‐subunit proteasome inhibitor (PI) in clinical
development for relapsed/refractory multiple myeloma (RRMM) and glioma. This study …